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Educating Providers about Psychopharmacology Basics: Bridging the Interdisciplinary Work
Among the PMHNP and Psychologists
Background: The purpose of this evidence-based change in practice is to increase the fund of
knowledge among psychologists, licensed clinical social workers, and talk therapists in outpatient
psychiatric settings by educating clinicians about psychopharmacologic basics and the role and
work of a psychiatric nurse practitioner during group supervision meetings. This can help bridge
the gap of psychopharmacologic knowledge between mental health providers with and without
prescriptive authority.
Problem: Evidence shows that psychologists with non-prescribing capabilities are not often trained
or educated about the very medications that their clients are often taking. Currently, psychotropic
medication education is not a standard aspect of psychology student training. There supervision
hours are comprised of time spent with patients and supervisors. If education is provided to bridge
the gap and promote interdisciplinary conversations between those with prescribing capability and
knowledge, the likelihood for understanding and supporting clients who are undergoing talk
therapy and psychopharmacologic treatment yields more cohesive patient care.
Methods: Databases including PubMed, World Cat, Ebsco Host, Google Scholar, and CINAHL
were used to assemble recent literature from 1990 to present. An expanded search to include
literature from 1990 to present to allow for a more robust sample of literature given the sparse
quantity of literature on the topic. A review of the literature regarding the current levels of
pharmacologic training for psychologists and the collaboration between prescribing and. nonprescribing healthcare clinicians was appraised. These articles were further narrowed by those that
were in the English language, and the articles used were those that pertained to the subject matter
the closest.
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Intervention: An educational presentation was provided to 8 psychologists working in an
outpatient private practice setting in the Southern California region. A pre-and post-survey was
provided to assess the utilization and necessity of pharmacologic education. In addition, a toolkit
containing this information as well as weekly interdisciplinary team meetings, subjects and further
opportunities for cross-collaboration were established as part of the psychologist supervision.
Results: Results show a 231% increase in the average confidence levels of providers in their overall
knowledge and education of psychopharmacology based on post-presentation assessment results
compared to pre-test results. Overall confidence on average between all questions and all providers
increased by 313% after the presentation based on pre and post test results, indicating a significant
positive impact of implementation.
Conclusion: There is a lack of knowledge regarding psychotropic medications among psychology
students. Education from mental health practitioners with prescribing capability and knowledge
can bridge the gap and promote interdisciplinary conversations between those with prescribing
capability and knowledge and those without. Through increased knowledge of psychotropic
medications psychology students provide more cohesive patient care.
Key Terms: ‘Psychologists’, ‘psychopharmacology’, ‘training’, ‘education’, ‘collaboration’,
‘health care providers’, and ‘prescribing.’
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Educating Providers about Psychopharmacology Basics: Bridging the Interdisciplinary
Work Among the PMHNP and Psychologists
Background
Professions that have the ability to prescribe psychotropic medication in California include
Psychiatrists, Primary Care Physicians, Psychiatric Pharmacists, Family Nurse Practitioners and
Psychiatric or Mental Health Nurse Practitioners because of their training which allows them to
do so. However, the Psychology Licensing Law provides that the practice of psychology does not
include the prescribing of drugs and does not authorize a psychologist to prescribe drugs or write
prescriptions. In fact, existing law additionally makes the encroachment of these provisions a crime
and unprofessional conduct, citing them as reason for disciplinary action by the Board of
Psychology (National Alliance on Mental Illness, 2020). Although psychologists may not be able
to prescribe, their practice guidelines may additionally create a fearfulness around psychologists
pursuing further learning about psychotropic treatment.
Given the lack of ability for psychologists to prescribe psychotropic medication, although
they often interact with patients on psychotropic medications and fellow prescribing clinicians ,
there is a lack in provision of education for psychologists often due to the argument of whether
psychologists should prescribe or not. Conversely, ignoring this gap in education and opportunity
for interdisciplinary team building around patients can have negative repercussions for patients
and providers alike. This paper will discuss the positive effect that education about psychotropic
medication has on psychologists and ultimately the work they do and patients they serve.
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Problem Description
Approximately 1,500 psychologists in the United States have fulfilled formal postdoctoral
training in psychopharmacology (Ax, Fagan, & Resnick, 2009). Given this gap in exposure or
extensive knowledge of the subject, it is clear why psychologists may hold an array of opinions
toward medications and what roles psychologists might have when it comes to psychotropic
medication. (Hayes, Walser, & Bach, 2002). Although many psychologists understand the benefits
that medication can provide their patients, there is a gap and often concern around the potential
side effects, abuse, risks, and over prescription of medication among psychologists (Hayes,
Walser, & Bach, 2002). This shows that there is a significant knowledge gap to be fulfilled.
Additionally, according to the American Psychological Association Center for Workforce
Studies (APA CWS, 2009) Survey of Collaboration and Prescribing 12 Psychology Health Service
Providers most psychologists collaborate with psychiatrists (89%), primary care physicians (79%),
other medical specialists (50%), nurse practitioners (51%), and over a quarter consult collaborate
with physician assistants (27%). Moreover, about 90% of psychologists regularly discuss
medications with physicians and the majority provide information about medications to patients
(APA CWS, 2009). The evidence reveals that while there is potential for interdisciplinary
approaches when it comes to psychopharmacology education, there is still a significant gap
between the cross collaboration of psychologists and healthcare professionals with prescriptive
authorities.
Setting
This project took place in a virtual meeting setting among outpatient psychiatric care group
of psychologists in training, some of which were marriage and family therapists and others licensed
clinical social workers who all shared working for a private practice in Pasadena, California.
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Meetings took place via zoom and were not recorded to respect the privacy of providers. Meetings
and presentations took place as part of weekly supervision requirements for psychologists in
training. Two presentations were held and hosted by the PMHNP candidate in training, and
continued educational modules were supported PMHNP candidate and in turn facilitated by the
psychologists, allowing them opportunities to present on their specialty and subject matters
including talk therapeutic models and approaches.
Specific Aim
Evidence shows that psychologists with non-prescribing capabilities are not often trained
or educated about the medications that their clients are prescribed in their training or school
curriculum. There is no standardized practice for psychology students in training gaining their
hours aside from assigned supervision hours to be completed with patients and supervisors. The
provision of education around psychotropic medication can promote interdisciplinary
conversations between those with both prescribers and non-prescribing psychologists who often
work with the same patients, but in unique capacities.
An initiative to educate clinical providers regarding basic psychopharmacologic principles
and create a pathway for interdisciplinary discussion between prescribing providers and nonprescribing providers was completed. Two educational presentations were provided to 8
psychologists working in outpatient private practice setting in the Southern California region. A
pre-and post-survey were provided to assess utilization and necessity of pharmacologic education.
In addition, a toolkit containing this information as well as weekly interdisciplinary team meetings,
subjects and further opportunities for cross collaboration were established as part of the
psychology student supervision. The goal was to increase non-prescriber knowledge about basic
knowledge of psychopharmacology during supervision time. Congruently, the goal was to increase
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competence and education of psychologists surrounding psychotropic medication. This was done
by measuring their level of education about the topic, their comfortability to ask questions about
the matter, and their comfortability to seek out further resources on the topic. This was done with
the goal of improving patient outcomes, increasing interdisciplinary communication, and creating
a fruitful learning experience between prescribing and non-prescribing mental health practitioners.
Available Knowledge
PICOT Question
Among non-prescribing mental healthcare providers including therapists, LCSW’s,
MSW’s and therapist associates, does the implementation of basic psychopharmacologic
principles education and training increase interdisciplinary communication and knowledge
compared to the standard without such training throughout the course of supervision trainings?
Search Method
Databases including PubMed, World Cat, Ebsco Host, Google Scholar, and CINAHL were
used to assemble recent literature from 1995 to present. A review of the literature regarding the
current levels of pharmacologic training for psychologists and the collaboration between
prescribing and non-prescribing healthcare clinicians was appraised. The following primary terms
were used in the search: ‘Psychologists’, ‘psychopharmacology’, ‘training’, ‘education’,
‘collaboration’, ‘health care providers’, and ‘prescribing. Searches were limited to complete, peerreviewed articles in English only. Articles from 1990 to present were used to provide ample
literature to select from. This yielded 32 articles which were further narrowed according to
justifiability to this project. A total of 14 articles were further examined for their framework to
teach psychopharmacology, the cross collaboration, and benefits of providing pharmacological
education to psychologists.
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Critical Appraisal of the Evidence
Appraisal Tool
All articles were appraised using the John Hopkins Research Evidence Appraisal Tool
(Dang & Dearholt, 2017) to conclude the level of evidence.
Integrated Review of the Literature
The Benefits of Bridging the Interdisciplinary Gap
Sammons and Brown (1997) compiled data from a program conducted by the Department
of Defense in 1991 which was designed to train doctorate level psychologists to prescribe
psychotropic medications. Trainees received didactic instruction and clinical training with the goal
to train psychologists to become proficient in the independent use of psychopharmacologic agents.
Because the foundational goal of this program was to train licensed psychologists to prescribe
psychotropics rather than create a new profession, there was an overall welcoming sense by other
prescribing professionals.
Prior to the initiation of this program, the narrative in the field included the sole emphasis
on whether a provider had prescriptive authority or not. However, this program leveled the playing
field as it exemplified that the implementation of sound, science-based training programs for
psychologists could yield an increase in confidence of the subject matter for non-prescribers. This
study exemplifies that psychotropic education for psychologist can decrease some of the animosity
which may be provoked by prescribing vs. non-prescribing mental health practitioners. The study
acknowledged the common interest and goal for prescribing and non-prescribing mental health
practitioners as excellent patient centered care.
In a similar study conducted by Wiggins and Cummings (1998), data was gathered from a
clinical operations company that was a practitioner driven managed behavioral care system.
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Results of this study showed that 68% of patients who presented for treatment with a psychologist
were already on psychotropic medication prior to coming in. Ultimately, only 22% of patients seen
in treatment were continued on their medications at the end of the 4-year compilation of the data
and 16% of participants had had their medication or dosages changed by their psychiatrist
following recommendations and interdisciplinary team meetings including the recommendations
by their treating psychologists or case managers. This showed that including and overlaying both
the therapist and prescribing care provider in the care affected the outcome and allowed room for
dialogue and planned individualized care of each patient based on their management, progress,
and tracked changes by the psychologist.
These older studies which were foundational for a significant call to action which took
place as an Ad Hoc Task Force Team assembled by the American Psychological Association
which called for more formal training in psychopharmacology. The Practice Guidelines Regarding
Psychologists’ Involvement in Pharmacological Issues created and revised by the American
Psychological Association in 2011 recognized that by 2000, an estimated 43% of patients seen by
psychologists were actively using psychotropic medications as part of their therapy. Additionally,
when this call to action and document was created, appropriately trained psychologists had
recently been granted prescriptive abilities in the states of Louisiana, New Mexico and the military
following the earlier findings of Sammons and Brown (1997). This document recognized and
clarified that psychologists interact specifically with psychotropic prescriptions at three different
levels: 1) When the psychologists is also the prescriber such as in the states of Louisiana, New
Mexico or in the military after specific training to do so, 2) As active collaborators in medication
decision making and lastly 3) Their provision of information which is relayed as relevant to
pharmacotherapy decision makers.
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Providing Education Equates to Increased Psychotherapy Knowledge
In a primary research study conducted among a group of psychology interns who were
given a brief educational course in psychopharmacology, follow-up questionnaires from the
participants indicated increased knowledge and confidence in their collaboration with physicians
(El Mallakh, 1994). Although this study was nonrandomized and small in sample size, 93% of
participants felt that the seminar should be continued, with over half of participants feeling that
the seminar had a positive effect on their clinical practice. This study exemplifies on a smaller
scale that brief psychopharmacology knowledge provision for psychologists is useful.
In another larger sample study example of how psychologists’ knowledge and training of
psychotropic medication improved patient outcomes, a randomized group of school psychologists
(N=320) were assessed for more information around their caseload and the percent of their children
and adolescent clients on psychotropic medication as well as their level of training in child and
adolescent pharmacology (Carlson et. al., 2006). The results of this study revealed that although
23% of the children and adolescents that they worked with on average were on psychotropic
medication at the time of the study, most of the training that the psychologists had in child and
psychopharmacology appeared to be from independent reading (96%). 80% of psychologist
participants stated that they had never taken a university-based course on psychopharmacology,
with 76% of those stating that a psychopharmacology course was not available at their school.
90% of participants also felt they were between not well trained and somewhat well trained in
psychopharmacology. Additionally, results revealed that 90% of school psychologists would not
opt to seek prescription privileges. Results from this study imply that school psychologists are
attentive to the gap between their formal training and their responsibilities related to medication
treatments, and moreover addresses the lack of confidence that psychologists in this study had
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when speaking with their clients about psychopharmacology. When surveyed, this study found
that 90% of participating psychologists would not opt to seek prescription privileges if they were
given the option.
Similarly, the literature review by Merla Arnold (2008) confirms that knowledgeable
psychologists can help reduce the frequency and severity of complications that occur among the
geriatric population such as falls or mental status changes often due to polypharmacy. This notes
that psychologists can serve as a touchpoint by developing a collaborative relationship between
the patient and prescriber. As the American Psychological Guidelines for Practice with Older
Adults (2004) notes, “It is important for any psychologist to be familiar with current information
about biological and health-related aspects of aging.” This can be extended and applied to
medication management as pharmaceuticals can have very distinct effects on these unique
populations, especially amid complications that Arnold notes can occur with polypharmacy in
aging adults.
Perspectives on Prescribing
Robiner et. al. (2003) advise caution and suggest that psychologist’s scope of practice
should not include prescribing given that their data reveals key gaps as well in psychologists’
training and limitation of their knowledge. Their research consisting of 49 doctoral level
psychologists who completed surveys in form of a quiz which assessed knowledge of
psychopharmacology and related medical information. Regarding knowledge of adverse drug
effects and contraindications, participants obtained an average of 30% as a whole group of
participants, 29% regarding knowledge of drug related clinical syndromes, and 36% average group
scores on the psychopharmacology quiz. Psychologists also reported reading significantly less than
psychiatric residents who were studied psychopharmacology. However, Carlson et., al. (2008) in
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the previous study had found that most of the training that the psychologists had in child and
psychopharmacology appeared to be from independent reading (96%), and Robiner et. al. (2003)
found that psychologists read an average of 0.35 books and an average of 7.5 articles about
choosing and using psychoactive medications, this shows the significant gap in foundational
knowledge and access to psychopharmacology foundational information for psychologists when
compared to those with prescribing authority despite their work with often the same patients.
Tompkins and Johnson (2016) conducted a similar study in Oregon where 397 selected
psychologists were surveyed online regarding their attitudes and knowledge about prescriptive
authority. While this study did not assess the direct knowledge of psychologists as it pertains to
psychotropics, it did examine their knowledge and feelings around the prescriptive authority for
psychologists’ movement (RxP). Findings revealed an overall lack of awareness of guidelines
regarding training qualifications to be able to pursue RxP, a significant knowledge deficit of which
states and territories currently have prescriptive authority, and a lack of knowledge to ender an
APA psychopharmacology training program. Additionally, the study addressed the large division
that exists between scope of expansion, with 43% of participants supporting improved access and
expansion of prescriptive authority, 32% of participants opposed to it, and 25% who remained
undecided. This further exemplifies that in addition to a lack of access to education about
psychopharmacology, the emphasis on whether psychologists should have prescriptive authority
can further complicate access aside from formal training with the aim to pursue prescriptive
authority across the board for psychologists to psychotropics education which not all psychologists
may want to consider or could do given the state in which they practice.
Aston et. al. (2021) studied the role that clinical psychologists in the United Kingdom have
in their client’s psychotropic medication by having 147 participants complete an online survey and
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specify involvement such as having the ability to impact a change in the client’s medication
regime. 98% of participants reported recent involvement with the clients’ use of psychotropic
medication and all reported being willing to have some form of involvement if given the
opportunity. Participants also participated in interviews in which their role as advocates and
wanting to seem knowledgeable was a noticeable trend in the resulted data. This shows that in
addition to their close work around medications with clients, participant sentiment about wanting
to seem well-informed while recognizing not having a full grasp of why the person may be taking
medication can create conflict, and hesitation which can in turn affect the care clients receive.
Because psychologists may often see the clients that the PMHNP does, but in a different capacity,
they may be trusted vessels and touchpoints of communication for the patient to interface with the
conversation of medication-based therapy.
Involving the Psychologist
In a similar study conducted by Vanden Bos and Williams (2000), 569 practicing
psychologists conducted a survey which reported the types of professional activities in which they
regularly engage with clients. Results showed that 99% of participants reported that they had
collaborated with physicians who prescribed psychotropics and other types of medication, with
only 1 % of participants indicated that they had never worked with a prescriber. Moreover, 96%
of participants reported having at least one patient taking psychotropic medication. The data
reflects the high involvement the psychologist has in the process of psychotropic medication
administration and maintenance. Additionally, Vanden Bos and Williams (2000) confer that
prescribers and psychologists may already have high involvement and interaction rates. However,
as prior studies have shown, psychologists may lack education, knowledge, and training around
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psychotropic medication and thus the cross-collaboration across disciplines may not be as robust
as it potentially could be for the benefit of the patients and providers alike.
Room for Cross Collaboration Between Disciplines
Robiner et. al. (2013) discusses that collaboration may be a compelling alternative to RxP.
While prior articles, discussions, and studies focus on the premise of increasing the knowledge of
psychologists around psychotropics and the argument of whether they should be allowed
prescriptive authority, Robiner et. al. (2013) argues that growing psychologists’ learning
connected to clinical psychopharmacology is recognized as having beneficial effect. In an analysis
completed by the APA Center for Workforce studies, over 90% of psychologists commonly review
medications with physicians with the majority also providing knowledge about psychotropics to
patients (APA CWS, 2009). The data reveals that cross-collaboration and interprofessional care
enriches the patient experience but do not rely on whether psychologists have prescriptive
authority. Additionally, to further those channels of communication between providers,
opportunities that can serve as both educational and collaborative spaces for clinicians and
psychologists alike are a tangible goal that shifts the focus from who has prescriber ability to room
for cross-collaboration between the various disciplines that work to improve the mental health and
wellbeing of those served.
What should be taught
Tomba et al. (2017) established what psychologists need to know about psychotropic
medications based on the domains of clinical psychopharmacology, noting that psychotropic drugs
may also affect the clinical presentation of mental disorder such as in the case of withdrawal
symptoms, which is also critical for the psychologist to note. It is argued that clinicians should
have familiarity with psychopharmacology, particularly the potential side effects in their patients,
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with an emphasis on the key domains of clinical psychopharmacology: 1) Psychological effects of
psychotropic drugs, 2) Likelihood of responsiveness, 3) Assessing side effects, 4) Behavioral
toxicity, 5) Interaction of Medical drugs with behavioral variables and psychotherapy.
Similarly, Ingersoll (2000) notes that psychologists should understand how taking
medication or the non-compliance of medication can affect a patient’s progress in their counseling
and therapy, as this can help them decide when to raise these concerns to the professional who
prescribed the client’s medication. As someone who taught and designed an elective course for
post-masters students in his study, APA guidelines which were established in 1995 were used to
denote Level-1 (established to train non-medical students of psychology and mental health
clinicians, more broad and generalized), Level-2 guidelines (training for working with particular
populations such as children or older adults who may take psychotropic medication) and Level-3
guidelines (meant to train psychologists for prescriptive opportunities depending on their level of
education and state practice guidelines). By taking parts of all training levels, Ingersoll (2000)
emphasized the following teaching principles: 1) Biological bases, 2) Principles of
Psychopharmacological Treatment, 3) Introduction to Clinical Psychopharmacology, and 4)
Classes of Psychotropic Medication. Teachings were didactic with visual aids and metaphors as
conceptual aids to help with the learning. Additionally, quizzes were given in small groups to allow
for learning.
Ingersoll (2000) also highlights the importance of who should teach the course, given that
the ACA (1995) Code of Ethics and Standards of Practice states that professionals should practice
within the boundaries of their competence, based on their education, training, supervised
experience, state and national credentials and professional experience. Thus, this role is suited for
the nurse practitioner in training given the knowledge, experience, and formal course training with
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medication management. Ingersoll (2000) notes that expanding the preparation, skills and
knowledge of non-prescribers who often interface with the same patients as prescribers on different
levels to help clients understand treatment options especially as medication based and therapeutic
based treatment often occur simultaneously.
Summary/Synthesis of the Literature
The articles chosen concentrated on the advantages of cross collaboration between
psychologists and their knowledge, understanding, and abilities around psychotropic medication.
The objective was to gather information about teaching psychopharmacology to psychologists, the
experience of psychologists with psychopharmacology, and the role that educating and crosscollaborating with psychologists could play for optimal patient-provider outcomes.
Rationale
The Psychobiosocial Model of Care (BPS) as explained by McGrath and Moore in their
work Integrating Pharmacotherapy and Psychotherapy (2010) consists of three key aspects which
provide the context for the execution of this project to help to bridge the gap of
psychopharmacologic knowledge that exists among mental health providers without prescribing
capabilities who may otherwise go without this knowledge. The first aspect of the BPS asserts that
psychologists via their training are taught a specialized skillset for addressing mental health
concerns via the psychological aspect of their patient’s lives and thus education and training in
pharmacology could add to extend their knowledge to be better prepared to address mental health
concerns. The second key aspect of the model asserts that psychologists could help patients choose
the least invasive and most biologically efficacious treatment based on their knowledge of the
patient and unique relationship with them in alignment with the prescriber. The third key aspect
of the model asserts that the social aspects of a patient’s dynamic such as interpersonal factors or
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the social interactions they may have shared with their psychologist or therapist which hold
motivational abilities given their patient provider relationship. BPS highlights the correlation
between biological, psychological, and socio-environmental aspects which, when applied to the
education and knowledge of mental health providers without prescribing capabilities,
demonstrates the impact that the provision of psychopharmacology education allows for an
increase in knowledge, confidence, and non-prescriber and prescriber alliance.
Methods
Context
Psychopharmacology knowledge is often provided as part of the curriculum for future
prescribers such as psychiatrists, psychiatric nurse practitioners, and some psychologists
depending on their respective state prescriber laws and level of education. Psychologists in the
state of California, practicing psychologists cannot legally prescribe medication as established in
section 2904 of the California Board of Psychology’s Business and professions Code (California,
Can California Psychologists Prescribe? 2014). However, this same code establishes that a
psychologist may discuss medications with a patient and may engage in collegial discussion with
a patient’s physician or prescriber regarding the appropriateness of medication for the condition
being treated. Additionally, it is noted that psychologists should in fact maintain a close
consultative connection with the prescribers to assure appropriate overall treatment of the patient.
Due to a lack of education and knowledge about psychotropic medication, psychologists and their
patients alike do not reap the benefits of the potential for improved outcomes that can exist with
increased knowledge about psychopharmacology to improve interdisciplinary care and care
outcomes.
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Intervention
This project aimed to increase this psychopharmacology education and knowledge for a
group of non-prescribing psychologists working with outpatient patients ages 5 and up as therapists
to improve their mental health and wellbeing as part of a private practice psychological services
group in Pasadena, California. A two-hour presentation that covered psychopharmacology basics
was provided by a Psychiatric Nurse Practitioner Doctoral Candidate Student at the site to 8
psychologists working in outpatient private practice setting via the telehealth platform doxy.me
for patient privacy and data compliance purposes. One hour and a half consisted of the presentation
and the remaining 30 minutes during the session was allotted for a 10 question pre-and post-survey
to assess utilization and necessity of pharmacologic education by assessing provider confidence
level in the topic, in addition to time for questions and discussions. A toolkit containing this
information in the form of an established resource library where providers could access this
presentation again was also provided at the conclusion of the project. The first presentation took
place in January of 2022 and the second took place in March of 2022. Data was collected, analyzed,
and was presented based on the educational presentation, however, this project sparked dialogue
and further presentations on other topics of interest to the psychologist team after initial
presentations took place. The ongoing presentations by other members of the team based on their
expertise continues to be implemented on a weekly basis.
To gain primary stakeholder support (Appendix F), a letter via email was sent to the two
directors and co-founder psychologists of the practice. After introducing the concept, a follow up
meeting was held to introduce the concept and discuss how this would benefit the practice. During
this initial presentation, co-founders were provided an outline of the proposed project, the project
outcomes, a cost analysis breakdown, and the proposed timeline of the project. Co-founders were
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also provided a copy of the pre and posttests as a form of self-assessment and to assert the need
for this project’s implementation. After this presentation, co-founders appeared on board and had
strong interest in the project as they noted it would increase their providers’ knowledge. Cofounders provided a letter of support to initiate this project (Appendix B). Timing of when the
project would occur for providers was also discussed, and it was determined that weekly company
meetings and weekly scheduled supervision time for associates could be re-allotted for this project.
After gaining stakeholder support, the 8 psychologists were briefed on what to expect
before the first educational presentation to gain their support and trust. By introducing herself prior
to the implementation of the educational presentations, Psychiatric Nurse Practitioner Doctoral
Candidate Student was able to establish a relationship with non-prescribing providers in the
practice. Additionally, the presentation was tailored to the learning styles, comments, and requests
which were provided by the psychologists during this preliminary meeting. The final versions of
both presentations consisted of a brief overview of basic psychopharmacologic principles and key
domains of clinical psychopharmacology as established by Tomba et. al. (2017). The primary
topics included: Psychological effects of psychotropic drugs, 2) Likelihood of responsiveness, 3)
Assessing side effects, 4) Behavioral toxicity, and 5) The interaction of medical drugs with
behavioral variables and psychotherapy. The presentation provided an opportunity for the
Psychiatric Nurse Practitioner Doctoral Candidate Student to serve as a knowledge base for nonprescribing providers and bridge the knowledge gap which providers expressed wanting to learn
more about.
The presentation created and adapted from knowledge learned in courses throughout the
Psychiatric Nurse Practitioner Doctoral Candidate Student’s educational journey as part of the
Psychiatric Mental Health Nurse Practitioner Curriculum at the University of San Francisco, with
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an emphasis on adaptations from learnings conducted through the psychopharmacology course.
Pre and post questionnaires were conducted before and after the presentation to assess the
confidence levels of providers in these topics before and after the intervention. Additionally, the
presentation was electronically distributed to the team via google drive with the formal
establishment and initiation of a company resource library so that providers could have access to
them as needed for reference. This led to a space for future presentations which were incorporated
by members of the team based on their expertise and the library of resources for providers in the
practice continues to evolve after the implementation of this initial project.
Gap Analysis
Evaluation and appraisal of the evidence shows that there is a significant gap between what
psychologists know and are taught regarding psychopharmacology, and the expectation that is part
of their role in the state of California establishes that although a psychologist may not prescribe,
they can and thus should discuss medications with a patient and may engage in collegial discussion
with a patient’s physician or prescriber regarding the appropriateness of medication for the
condition being treated. Additionally, although psychologists should in fact maintain a close
consultative connection with the prescribers to assure appropriate overall treatment of the patient,
studies show most psychologists may never have taken a university-based course on
psychopharmacology, in large part because a psychopharmacology course may not have been
available at their school. Moreover, most psychologists in studies have also expressed that they
were between not well trained and somewhat well trained in psychopharmacology (Carlson et. al,
2008). Similarly, the pretests provided to non-prescribers for this project also showed low
confidence in core psychotropic and psychopharmacologic principles (Appendix M). Additionally,
the practice did not appear to have a toolkit or resource library which could make this knowledge
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available for clinicians prior to this project. The educational presentations were aimed to increase
knowledge, confidence, and ultimately bridge the psychopharmacologic gap among prescribers to
ultimately produce improved patient provider experience and prescriber- psychologist
interdisciplinary collaboration as described in the Gap Analysis for this project (Appendix E).
Gantt Chart
Appendix G notes that this project initially began with the gaining an understanding of
what the need was for a project implementation at the student’s clinical site. Once a need and gap
analysis were conducted, a literature review and further analysis of the research began in March
of 2021. Upon completion of gathering of the evidence, an initial outreach email to coordinate a
meeting with the co-founders of the company was sent in September of 2021. In October of 2021,
the project goals in alignment with the research were established and compiled into a presentation
which during an initial meeting allowed the student to express project interest, connect with cofounders, and allow time for any questions they had. A letter of support was received in November
of 2021. Once their approval was gained, the project gained additional approval from primary
academic advisor Dr. Trinette Radasa at the University of San Francisco upon a virtual meeting
which took place with the student implementing the project to further discuss the project’s details
in November of 2021. In December of 2021, the student attended a preliminary introductory
meeting with non-prescribing psychologists of the company. Following their feedback and this
initial meeting to meet with psychologists, research was compiled to create the educational
presentation along with the pre and posttests. The educational presentation and administration of
the pre and post tests for non-prescribing clinicians took place in January of 2022. Data was
collected and compiled between February and April of 2022. The student attended a follow up
meeting with the entire company team including the co-founders for further questions, findings,
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and production as well as distribution of the resource library were provided in late April 2022 at a
follow up meeting with all members of the company, including co-founders. The written
presentation of this project took place thereafter.
Work Breakdown Structure
The Work Breakdown Structure (WBS) for this project allowed for the timely
implementation of this project (Appendix H). The WBS classified 14 steps which were pivotal in
the planning, implementation, and evaluation of the project. The WBS planning phase included
gaining stakeholder support, creating a timeline and draft of the goals for the project, and gathering
all materials and supplies. The Implementation phase included the actual presentation and creation
of a virtual space for the presentations to be accessed. Lastly, the evaluation phase sought to
compile the data from the surveys throughout the project and the reporting of results back to the
key stakeholders as well as participants for their feedback. Additionally, the final phase and part
of the WBS of this project included the gathering of this written report.
Responsibility/ Communication Plan
An initial meeting with program advisor and Doctor of Nursing Practice (DNP) chair at the
University of San Francisco was held to discuss the project in its infancy stage. The student and
Dr. Radasa communicated via email, zoom meetings and text message. Additionally, exchanges
between the key stakeholders and co-founders of the psychiatric company also took place via
email, zoom meetings, and text messages (Appendix I). Once the project was established,
communication about these presentations to the non-prescribing psychologists and providers of
the company took place during the weekly group session time that all providers of the company
attend on a weekly basis. In efforts to establish trust between the presenting student and providers,
an introduction of the student by the co-founders was made to the group at one of these group
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meetings prior to the actual presentations. Email invitations were also sent to providers via the
company google calendar and company emails. The presentations were held via zoom. To
facilitate communication, providers were also given the student’s company email, company phone
number, and the presentations were provided as part of the project in the form of a google drive
folder which facilitated the beginning of the building out of the company’s resource library which
has since grown.
SWOT Analysis
A SWOT analysis was conducted to measure the strengths, weaknesses, opportunities, and
threats at the psychological services company (Appendix J). This SWOT analysis identified key
areas in which the educational presentation could improve overall performance, particularly on the
non-prescriber clinician end. One major strength of this project which made it feasible for the
company was the overall cost. Because the student who presented was completing clinical hours,
unpaid, and the project itself consisted of using digital mediums of distribution which the company
already had implemented prior to the project, the cost of development, materials and time was
supportable. Additionally, because the presentation was distributed to providers for further
viewing or resourcing after via the creation of a digital resource library on the company’s Google
Drive, unlimited access appeared to be another major strength. However, this was also an apparent
weakness given that the project outcomes are only as good as the providers using, reinforcing, and
ultimately dedicating time to learn the information. Additionally, given that previous provider
education and interest on the topics varied, the enthusiasm to learn may have as well. An
opportunity of the project included the start of a virtual resource space for providers of the
company which has since the implementation of this project expanded by the contributions of
providers according to their expertise and knowledge. This project also serves as an opportunity
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for other providers to implement their knowledge and education to other members of the team. A
threat appears to be that psychopharmacology and the learnings provided in this project require
time and continued education. While this was a great start for providers to be exposed and to peak
provider interest as well as provide an opportunity for cross collaboration within the company
personnel, providers may also benefit from continuous learning and presentations.
Budget and Financial Analysis
The implementation project sustained a higher initial development cost when compared to
the projected long-term savings to be produced for the company. The budget created for this project
consisted of a projected cost assuming the company would not cover certain items and an actual
adjusted cost which excluded the items provided by the company, given that these presentations
were held virtually. The initial startup cost of the project, which included two educational
presentations was appraised at a projected cost of $14,350 and an actual adjusted cost, excluding
the items provided by the company of $5,800 (Appendix K). This significant cost reduction was
due to the provision of technological materials supplied by either each provider or the company,
including electronic devices, Wi-Fi and internet access, as well as a zoom subscription. This
budgeted for the materials used in the training and the cost of labor to produce the presentations in
form of time and the costs of materials. While the student was not paid as this time was factored
into clinical hours, if the student would have been paid for this project, it was budgeted at $65/hour.
Ultimately, the compensation for the student’s project would amount to 68 hours at $65 per hour
for a total of $4,420 in labor costs. Although these estimates provide a rough budget and
breakdown based on projections, it is estimated that the projected return of investment is projected
to surpass the initial startup costs given that it would ultimately result in a long-term savings of an
estimated $5,000 annually via improved provider collaboration and patient care outcomes.
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Study of the Interventions
In efforts to conclude the influence of the educational project implementation, a 7 question
pre and posttests as a form of self-assessment was provided to each clinician (Appendix D). These
assessments indicated the baseline knowledge based on confidence in the subject matter and
knowledge gained after the educational presentation intervention. The change in scores from the
pre to post test was a form of evaluating the knowledge growth of participants. Additionally, this
form of assessment aligned with the work of prior researchers in the field (Carlson et. al, 2008).
Outcome Measures
In efforts to quantify the outcomes of the implementation of the project, a 7 quantitative
pre and posttest were provided to each non-prescribing physician. Multiple opportunities for
clinicians to provide feedback were also included as part of the periodic meetings and between the
presentation to implement said feedback. Feedback was also collected at the conclusion of each
pre and posttest which were administered via a google survey.
The pre and posttests contained the same 8 questions with 7 assessing key aspects of the
confidence level of non-prescribing psychologists in the fundamental and key topics of
psychopharmacology. Additionally, the 8th question was included in the survey to assess for any
feedback or commentary. This feedback and commentary were compiled and assessed qualitative
data, while the changes in scores from before to after the presentation were assessed as quantitative
data. The quantitatively measurable questions measured the confidence of providers on the topic.
The 8th question which was a free-form text fillable question allowed providers to share additional
thoughts and comments (Appendix D). It is important to note the presentation is a small aspect of
psychopharmacology and goal of the presentation was to begin the conversation as well as identify
value in psychopharmacology education.
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Data Collection Instruments
Quantitative and qualitative data were first captured as responses on a google form and
analyzed using Microsoft Excel. Pre and posttests did not include any participant identifiable
information. Given that the pre and posttests results were formatted as google surveys, results were
automatically populated into a table which aided in data management. The feedback and
commentary (qualitative) data from the surveys was captured as a word cloud to notably identify
any patterns or similarities between the feedback (Appendix P and Q). Additionally, a Plan-DoStudy-Act model was created for the continual improvement and process of the project given that
the implementation of this educational presentation has led the way for other educational
endeavors for the company team members (Appendix L).
Analysis
Pre and post-test results were collected via google surveys upon completion of the project
presentation. These assessments were then compiled and presented at a later all-staff company
meeting, including stakeholders to show the importance and statistically significant benefit of
continued education in the realm of psychopharmacology for non-prescribers working at the
practice. The responses were also used to show that while non-prescribing psychologists are
expected to form opinions and share their knowledge with patients as well as communicate and
cross collaborate with prescribing providers in accordance with the California state practice
guidelines, they are not necessarily equipped to do so. Additionally, this analysis showed that
educational presentations as such not only increase knowledge and confidence of clinicians, but
also expands on the need to create space for continuing learning resources and cross collaboration
among company mental health practitioners.
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Ethical Considerations
Provision 6 of the American Nurses Association Code of Ethics for Nurses establishes that
the nurse, through individual and collective effort, establishes, maintains, and improves the ethical
environment of the work setting and conditions of employment that are conducive to safe, quality
health care (2013). Given that a large part of the Psychiatric Nurse Practitioner’s role is knowledge,
familiarity, and prescriptive abilities, providing education to fill the gap that may exist for
providers who do not necessarily have prescriptive abilities but work with clients who are taking
psychotropic medication is critical in maintaining and furthering a safe practice environment.
Similarly, provision 8 of the American Nurses Association Code of Ethics for Nurses establishes
that the nurse collaborates with other health professionals and the public to protect human rights,
promote health diplomacy, and reduce health disparities (2013). This educational model also
allowed for the collective opportunity for all levels of mental health practitioners working at the
company to establish a working relationship with each other and fostered cross collaboration
between the distinct roles that practitioners play respectively with patients. Like solidarity and
kinship which are both rooted in the Jesuit educational values, it is important that despite our
differences in abilities and practice guidelines as providers, that we continue to foster relationships
and community with those we work with and ultimately serve as a collective people for others
(University of San Francisco, 2018).
A secondary aim of this project is to reduce health disparities for patients. Given the
stigmas that may exist with psychotropic medications, along with the hurdles that patients may go
through including the correct authorizations and referrals to get to a provider, a psychologist or
therapist may be the first encounter and great first step in this process if that patient could
ultimately benefit from psychopharmacology. Additionally, many patients served at the practice
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where the project took place are Spanish speaking with Spanish being the primary language for
many clients. To accommodate for this, most providers at the company also speak Spanish. Thus,
incorporating and providing education for these providers who very well may be the first and only
touchpoint into the patients’ mental health and wellbeing, it is the ethically correct stance to assure
they are well equipped and informed to support the populations served.
Results
The results of this pre and post test results were compiled into diagrams to display the vast
improvement in knowledge and confidence of non-prescribing psychologists after the
implementation of the project (Appendix M, N, O, P, Q). Results show a 231% increase in the
average confidence levels of providers in their overall knowledge and education of
psychopharmacology based on post-presentation assessment results compared to their pre-test
results. There was a 188% increase in average provider confidence in overall knowledge of
psychological effects of psychotropic drugs. There was a 333% increase in confidence about
overall knowledge of the behavioral toxicity that can occur with psychotropic drug and regarding
confidence about overall knowledge of the interaction of medical drugs with behavioral variables
of psychotherapy. There was a 550% increase in confidence in provider ability to seek out
resources related to psychopharmacology and a 676% increase in the average confidence of
provider access to resources. Overall confidence on average between all questions and all
providers increased by 313% after the presentation based on pre and post test results, indicating
the significantly positive impact that the implementation of the project had.
The pre and posttests contained the same 8 questions. 7 of the questions assessed the nonprescriber clinician confidence about key topics in psychopharmacology before and after the
educational presentation intervention. The 8th question allowed providers to fill in commentary,
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and feedback which served as a form of qualitative data for the intervention (Appendix P and Q).
Results showed that regarding confidence in their overall knowledge and education of
psychopharmacology, non-prescribing psychologists before the presentation were on average
between not at all confident and somewhat confidence in psychopharmacology. After the
educational intervention, providers were somewhere between somewhat and completely confident
in their overall knowledge and education of psychopharmacology. Similarly, prior to the
intervention, clinicians regarded their confidence on average in overall knowledge of
psychological effects that psychotropic drugs can have as somewhere between not at all confident
and somewhat confident. The average for this confidence level also appeared to increase after the
intervention to somewhere between somewhat confident and completely confident. Regarding
their confidence in knowledge of responsiveness and side effects that psychotropic drugs can have,
providers rated their confidence on average as slightly confident, while after the presentation, all
providers shared in feeling between fairly and completely confident about this. Providers ranged
from not at all confident to slightly confident in their knowledge of behavioral toxicity which can
occur with psychotropic drugs prior to the intervention, and the average of this response increased
to be between fairly and completely confident after the presentation. Provider confidence in
knowledge of the interaction of medical drugs with behavioral variables of psychotherapy that can
occur with psychotropic drugs was on average slightly confident, while after the presentation, most
providers felt between fairly and completely confident in this. Regarding confidence in their ability
and access to seek out resources related to psychopharmacological treatments, confidence among
providers increased from not at all and slightly confident to fairly and completely confident after
the intervention. The 8th question which allowed providers to fill in commentary, and feedback
and served as a form of qualitative data for the intervention displayed a variety of comments and
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a pattern of terms and phrases including “thank you,” and “great” were included in the word cloud
(Appendix P and Q).
The responses from the pretest questions prior to the educational intervention overall depict
an overwhelming initial low level of confidence among providers (Appendix M). Conversely, the
responses from post-test interventions which were completed after the educational intervention
depict an overall increase in confidence, with providers indicating somewhat to fairly confident at
the conclusion of the intervention (Appendix O).
Discussion
Summary
This project emphasizes the need to increase the fund of knowledge among psychologists,
licensed clinical social workers, and talk therapists in outpatient psychiatric settings by educating
clinicians about psychopharmacologic basics and the role and work of a Psychiatric Nurse
Practitioner who is in the prescriber role. As the evidence suggests, psychologists with nonprescribing capabilities are not often trained or educated about the medications that their clients
are taking. The practice guidelines for psychologists indicates that they should serve as a liaison
between the patient and prescriber and given the interface that psychologists and therapists have
with clients. Non-prescribers can serve to promote and establish interdisciplinary care which
would improve patient outcomes.
Interpretation
If education is provided to bridge the gap and promote interdisciplinary conversations
between those with prescribing capability and knowledge, the likelihood for understanding and
supporting clients who are undergoing talk therapy and psychopharmacologic treatment yields
more cohesive patient care. This can help to bridge the gap of psychopharmacologic knowledge
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that exists among mental health provider without prescribing capabilities who may otherwise go
without this knowledge.
Limitations
Because this project was implemented among a small group of psychologist providers who
work solely in an outpatient setting with patients ages 5-90, one major limitation is the small
sample size of psychologists who received the intervention and the limited groups of patients they
work with. This is a limitation because this intervention was suited to fit medications and
treatments most common to outpatients and may not be as generalizable for other pharmacologic
treatments in other higher level of care patient provider settings. Additionally, this project was
instituted at a practice and among non-prescribers in the State of California, while recognizing that
here psychologists do not have the ability to prescribe. Given that practice guidelines for both
psychologist and other healthcare practitioners may vary in different states, it is important that this
be noted as certain providers or states may already be providing more robust education around
psychopharmacology to all mental health providers irrespective of their ability or inability to
prescribe.
Given the debate that exists around who should prescribe, much of the research to date pits
the prescriber against the non-prescriber and most of the research completed suggests this as a
reason to provide or not provide education around psychopharmacology. Instead, research moving
forward should focus on assuring that providers are well equipped to serve their patients by having
a conversation about psychiatric medication and feel comfortable discussing the topic, rather than
pitting the prescriber role as the only beholder of said education.
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Conclusion
Although psychologists may not receive standardized education and training about
psychopharmacology, it is important that all mental health professionals working with patients to
improve their mental health and well-being be provided with foundational education and
knowledge for the benefit of the patient. Especially given the stigmas that may exist with
psychotropic medications, along with the hurdles that patients may go through including the
correct authorizations and referrals to get to a provider, a psychologist or therapist may be the
patient’s first encounter. Thus, a psychologist who is well equipped to discuss
psychopharmacologic treatment can be a pivotal touchpoint in assuring the patient receives further
medication support by a prescriber. Education by a mental health practitioner with prescribing
capability and knowledge can bridge the gap and promote interdisciplinary conversations between
those with prescribing capability and knowledge.
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scores
measuring
knowledge
and
confidence to
collaborate
with
physicians

N=50
student
s in a
course
at one
given
time

Independent:
Curriculum of
psychopharma
cology

Critical
Appraisal:
Level II,
High Quality
Strengths:
Paved way
for future
research to
be conducted
Limitations:
Small sample
size, not
much detail
about
questionnaire
or group of
participant
demographic
s. Research is
from 1994.
Critical
Appraisal:
Level II,
High Quality

Strengths:
Conducted
editorial by
current
professor
who
teacher’s
psychopharm
acology
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methods.
Counselor
Education
and
Supervision,
40(1), 58–
69.
https://doi.o
rg/10.1002/j
.15566978.2000.t
b01799.x

the
structure,
developmen
t and goals
of courses
offered in a
counselor
education
program at a
midsize
state
university

cological
principles

students via
quizzes

part of
commitme
nt to
strengtheni
ng
education

Limitations:
Was not a
study with
design or
outcomebased
measures;
provides
basis for
teaching
psychopharm
acology but
does not
report back
results was
not
interventiona
l
Critical
Appraisal:

Robiner, W.
N.,
Bearman,
D. L.,
Berman, M.,
Grove, W.
M., Colon,
E.,
Armstrong,
J., &
Tanenbaum,
R. L.
(2003).
Prescriptive
Authority
for
Psychologis
ts: Despite
Deficits in
Education
and

Design:
Case
Controlled
Cohort
Study
Method:
Psychologis
ts were
recruited to
complete
surveys that
assessed
educational
background,
knowledge
related to
psychophar
macology,
readings
related to

N=49
Doctora
te
prepare
d
psychol
ogists

Independent:
Survey
Questions

Independent:
Responses of
psychologists
(nonN=20
prescribers)
Psychia vs.
tric
psychiatrist
Residen physicians
ts at
(with
least at prescribing
into
capability)
year 3
of their
psychia
tric
residen
cy

Measurement:
Survey scores
which
measured
educational
background,
knowledge of
psychopharma
cology and
related medical
information,
reading about
psychopharma
cology, the
effects of this
reading and
knowledge,
estimates of
prescribing
competence,
and

Results
show gaps
in
psychologi
st training
and
limitations
in
knowledge
pertaining
to
psychophar
macology
when
compared
to the
scores of
psychiatrist
s.

Level V,
Medium
Quality
Strengths:
More recent
study in the
field.
Compares
two types of
clinicians
who both
work with
the same
patients for
different
reasons
which
promotes
consistency
in the study
Limitations:
There were a
far smaller
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Knowledge?
Journal of
Clinical
Psychology
in Medical
Settings,
10(3), 211–
221.
https://doi.o
rg/https://do
i.org/10.102
3/A:102541
9114038

Robiner, W.
N., Tumlin,
T. R., &
Tompkins,
T. L.
(2013).
Psychologis
ts and
medications
in the era of
interprofessi
onal care:
Collaboratio
n is less
problematic
and costly
than
prescribing.
Clinical
Psychology:
Science and
Practice,
20(4), 489–
507.
https://doi.o
rg/10.1111/
cpsp.12054

prescribing
and attitudes
about
psychologist
prescriptive
authority.
They were
compared
via the same
surveys to
psychiatric
medically
trained
prescribers
and
residents.
Design:
N=
Editorial
N/A
Method:
Articles
pulled from
that have
been peer
reviewed
and
compiled to
focus on
and assert
that
interprofessi
onal and
teamwork
including
psychologist
collaboratio
n such as
with the
prescription
opportunitie
s (RxP),
along with
distinctions
in
psychologist
s’ education

psychologists’
views on
prescriptive
privileges for
psychologists

Independent:
Literature,
statistics, and
data
extrapolated
Dependent:
The analysis
of the way
intercollaboration
and inclusion
of
psychologist
collaboration

number of
psychiatrist
participants
and thus
perspectives
when
compared to
the number
of
psychologist
participants

Critical
Appraisal:
Level II,
High Quality
Measurement: While RxP Strengths:
Projected cost could be a
Acknowledg
over time after pivotal
es RxP as a
implementatio opportunity program
n of RxP
for cross
available to
program.
collaborati some
on,
psychologists
concerns
and how
include
much of
educational prescribing
background abilities
and
depend on
training, as state practice
well as lack guidelines
of financial which may
data that
vary
supports
the
Limitations:
interventio May not be
n
generalizable
to areas or
clinicians
who do not
have the
opportunity
to pursue
RxP.
Acknowledg
es is new
program, not
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is
deliberated

Sammons,
M. T., &
Brown, A.
B. (1997).
The
Department
of Defense
Psychophar
macology
Demonstrati
on Project:
An
Evolving
Program for
postdoctoral
education in
psychology.
Professional
Psychology:
Research
and
Practice,
28(2), 107–
112.
https://doi.o
rg/10.1037/
07357028.28.2.1
07

Design:
Systematic
Review;
Case Series

Tomba, E.,
Guidi, J., &
Fava, G. A.
(2017).
What

Design:
Articles
pulled from
that have
been peer

enough
financial data
to support
initiative yet.

N=3
curricul
ums
reviewe
d

Method:
Archival
reference to
prior
programs
via review
of 3
different
curriculum
and models
for training
psychologist
s in field of
psychophar
macology

Independent:
Type/curricul
um model and
revisions/vari
ations of
curriculums
Dependent:
Review of
various
curriculum
models

N=
N/A

Independent:
Literature,
statistics, and
data
extrapolated

Critical
Appraisal:
Low Quality,
Level V
Measurement: The United Strengths:
Courses and
States
Conducted in
contact hours
Uniformed partnership
which varied
Services
with the
by curriculum University Department
model and
of Health
of Defense in
course
Sciences
effort to train
(USUHS)m more
odel
doctoral level
contains
psychologists
the
to prescribe
essential
psychotropic
training
medications;
elements
holds
necessary
credibility
to produce
safe and
Limitations:
effective
Does not
prescribers report follow
and should up findings,
serve as an report is
example
from 1997
for
and no
psychologi update found
sts and
in the
educators
literature
moving
since
forward.
Critical
Appraisal:
Level IV,
High Quality
Measurement: Domains of Strengths:
Expert analysis clinical
Pulls from
from
psychophar various other
pharmacology macology
data sources
experts and
should be
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psychologist
s need to
know about
psychotropi
c
medications
. Clinical
Psychology
and
Psychothera
py, 25(2),
181–187.
https://doi.o
rg/10.1002/
cpp.2154

Tompkins,
T. L., &
Johnson, J.
D. (2016).
What
Oregon
psychologist
s think and
know about
prescriptive
authority:
Divided
views and
data-driven
change.
Journal of
Applied
Biobehavior
al Research,
21(3), 126–
161.

reviewed
and
compiled to
focus on
practical
pearls found
useful in
teaching
psychiatric
residents
and
practicing
physicians

Design:
Randomized
Control
Trial
Method:
Psychologis
ts were
surveyed
online
regarding
their
knowledge
and attitudes
of
prescriptive
authority
following
Oregon’s
decision to
veto the

Dependent:
The analysis
of the most
important
aspects of
teaching
psychopharma
cology

Control
N=203
psychol
ogists
in
Oregon
Educati
on
Group
N=194
psychol
ogists
in
Oregon

current
teachers in the
field

used as a
basis for
teaching
psychophar
macology
as they
cover key
aspects of
their
benefit,
characterist
ics,
vulnerabilit
ies and
interactions
.

and studies
to build case
Limitations:
Appears
written for
teachers of
those who
are capable
of
prescribing;
does not
mention
teaching the
subject
matter to
those without
prescriptive
abilities

Critical
Appraisal:
Low Quality,
Level V
Independent: Measurement: 43% of
Strengths:
Education and Online surveys psychologi Large
information
which assessed st were in
number of
regarding
the percentage favor of
participants;
access,
of scope of
scope of
study
training,
expansion
practice
occurred
legislation,
about attitude
expansion
right after
and education and shift of
to
RxP and this
views that
prescribe,
allowed for
Dependent:
Oregon
while 32% dialogue
Post test
psychologists
opposed
between the
scores
have around
being in
nonassessing
prescriptive
favor of
prescriber
knowledge,
authority
this. 6.3%
community
views, and
of
with respect
attitudes on
participants to this lack of
prescribing
in the
legislative
control
approval for
group
the program
knew about In Oregon
which
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https://doi.o
rg/10.1111/j
abr.12044

VandenBos,
G. R., &
Williams, S.
(2000). Is
psychologist
s'
involvement
in the
prescribing
of
psychotropi
c
medication
really a new
activity?
Professional
Psychology:
Research
and
Practice,
31(6), 615–
618.
https://doi.o
rg/10.1037/
07357028.31.6.6
15

RxPbill.
Participants
were
assigned a
control or
education
group which
completed
postinterven
tion
measures.

Design:
N= 596
Retrospectiv psychol
e Case
ogists
Controlled
Study
Method:
596
practicing
psychologist
s responded
to a survey
reporting
the types of
professional
activities
they engage
with
patients in
the realms
of
medication
and
psychophar
macology

states allow
prescriptive
authority
for
psychologi
st and only
7.6% of
participants
stated they
wanted to
get
involved
with
legislative
action
behind this
movement.

Limitations:
Study
completed
for
psychologists
in Oregon;
may not be
applicable as
practice
guidelines
vary from
state to state.

Critical
Appraisal:
Level I,
High
Quality
Independent: Measurement: 95% of
Strengths:
Survey
The percentage psychologi Surveyed
questions
of patients that st worked
randomly
psychologists
in setting
selected and
Dependent:
see and their
where
recruited
Actively
amount or
psychotropi actively
practicing
level of service cs were
practicing
psychologists’ which resulted routinely
psychologists
responses
in
used. 99% across the
psychopharma of
United States
cological
psychologi registered as
engagement
st reported members of
with the patient having
the APA in
for various
collaborati both
services
on with
inpatient and
physicians outpatient
who
settings
prescribed
psychotropi Limitations:
c. 96% of
Data is from
psychologi 2000, the
sts reported number of
at least one patients
patient of
taking
theirs
psychotropic
taking
medication
psychophar may have
macologic since
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medication
s.

Wiggins, J.
G., &
Cummings,
N. A.
(1998).
National
Study of the
experience
of
psychologist
s with
psychotropi
c
medication
and
psychothera
py.
Professional
Psychology:
Research
and
Practice,

Design:
Retrospectiv
e Case
Control
Study
Method:
Analysis of
episodes of
treatment to
affirm the
extent of
experience
psychologist
s have in
providing
care for
patients
taking
psychotropi
c
medications

N=
1,639,8
02
cases
analyze
d

Independent:
Patients with
episodes of
treatment
between July
1988July1992
Dependent:
The level of
experience
and interface
psychologists
have with
their patients
that take
psychotropic
medication

Measurement:
1) How much
experience
psychologists
have with
patients taking
psychotropic
medications 2)
The level of
participations
that
psychologists
have in
treatment
interventions
3) How
effective the
management
by
psychologists
of patients
taking

8,000
psychologi
sts were
involved in
at least
9000,000
psychophar
macologica
l treatment
episodes or
with
patients
taking
psychotropi
c
medication,
or 10% of
all licensed
psychologi
st between
the 4-year
period

changed.
Does not
differentiate
if
psychologists
’ patient is
taking more
than one
psychotropic
medication.
Relies on
psychologist
estimate and
report back
of data, no
interface of
data directly
with the
patient.
Critical
Appraisal:
Level III,
High Quality
Strengths:
Large sample
size over the
course of
many years
Limitations:
Study data
pulled from
patients in
outpatient
facilities
using
Medicate
system to
report; does
not capture
beyond this
population.
Critical
Appraisal:
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29(6), 549–
552.
https://doi.o
rg/10.1037/
07357028.29.6.5
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as part of
their
treatment

Zisook, S.,
Glick, I. D.,
Jefferson, J.
W.,
Wagner, K.
D.,
Salzman,
C., Peselow,
E. D., &
Stahl, S.
(2008).
Teaching
Psychophar
macology
What
Works and
What
Doesn’t.
Journal of
Clinical
Psychophar
macology,
28(1), 96–
100.
https://doi.o
rg/https://do
i.org/10.109
7/jcp.0b013
e3181603f6
b

Design:
Editorial
Method:
Articles
pulled from
that have
been peer
reviewed
and
compiled to
focus on
practical
pearls found
useful in
teaching
psychiatric
residents
and
practicing
physicians

N=
N/A

Independent:
Literature,
statistics, and
data
extrapolated
Dependent:
The analysis
of the most
important
aspects of
teaching
psychopharma
cology

psychotropic
medications
are 4) How
safe it is for
psychologists
to manage
psychopharma
cologic
treatment
Measurement:
Expert analysis
from
pharmacology
experts and
current
teachers in the
field

Level III,
High Quality

Lecture
strategies,
supervision
, teaching
pharmacolo
gy specific
to the
patient
population,
teaching in
accordance
to
guidelines,
and
teaching
the
transition
of learning
to practice,
as well as
assessing
learning
are key
aspects of
teaching
psychophar
macology

Strengths:
Pulls from
various other
data sources
and studies
to build case
Limitations:
Appears
written for
teachers of
those who
are capable
of
prescribing;
does not
mention
teaching the
subject
matter to
those without
prescriptive
abilities
Critical
Appraisal:
Low Quality,
Level V
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Appendix D. Pre-Test and Post Test Screening Tool and QR Codes
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58

59

Pre-Test QR Code and Link

Post-Test QR Code and Link

https://forms.gle/yLfA9EL4KbJsyM5i8

https://forms.gle/r9D3jKThYKpPsFbk8
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Appendix E. Gap Analysis

Problem

Goals

Gap

Evidence shows that psychologists with non-prescribing capabilities are not
often trained or educated about the very medications that their clients are
often taking. There is no standardized practice for psychology students in
training gaining their hours aside from assigned supervision hours to be
completed with patients and supervisors.
1. Increase confidence of non-prescribing mental health practitioners
about psychopharmacology
2. Increase knowledge of non-prescribing mental health practitioners
about psychopharmacology
3. Provide interdisciplinary space to foster cross collaboration between
prescribing and non-prescribing providers to increase
interdisciplinary care
If education is provided to bridge the gap and promote interdisciplinary
conversations between those with prescribing capability and knowledge,
the likelihood for understanding and supporting clients who are undergoing
talk therapy and psychopharmacologic treatment yields more cohesive
patient care.

An educational presentation was provided to 8 psychologists working in
outpatient private practice setting in the Southern California region were
provided. A pre-and post-survey were provided to assess utilization and
Implementation necessity of pharmacologic education. In addition, a toolkit containing this
information as well as weekly interdisciplinary team meetings, subjects and
further opportunities for cross collaboration were established as part of
their supervision.

Evaluation

In efforts to quantify the outcomes of the implementation of the project, a
10 quantitative pre and posttest were provided to each non-prescribing
physician. Multiple opportunities for clinicians to provide feedback were
also included as part of the periodic meetings and between the
presentation to implement said feedback. Feedback was also collected at
the conclusion of each pre and posttest which were each administered via a
Google survey.
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Appendix F. Stakeholder Analysis

Co-Founders
Prescribers

Power

Keep Satisfied

Psychologists

Manage Closely

Support Staff
Patients

Monitor

Keep Informed

Interest
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Appendix G. GANTT Chart
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Appendix H. Work Breakdown Structure

Educating Providers
without prescriptive
authority about
Psychopharmacology

PMHNP Student

Development of an
Educational
Presentation about
the basics of
Psychopharmacology

Development of a
Pre/Post Test

Assess Knowledge

Assess Confidence

Present Training

Provide Resources for
further
viewing/knowledge

Evaluation of the
Presentation

Collect and compile
quantitative data from
pre/post test

Collect and compile
qualitative data and
feedback from
pre/post tests

Create visuals to
support data analysis

Create visuals to
support data analysis

Present Findings
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Appendix I. Responsibility and Communication Matrix
Communication

Purpose

Medium

Frequency

Audience

Meeting with
program advisor

Introduce project and
review objectives and
goals; assure algins with
university goals

Via zoom

Once

Program advisor and
chair Dr. Radasa

Stakeholder
meeting

Introduce project and
review objectives and
goals; gain support from
co-founders of company

Via Zoom

Once

Co-Founders of CALA
Psychological Services

Introduction to
Psychologists and
non-prescribing
clinician team

Build trust and initial
fostering of relationship

Via Zoom

Once, during
weekly
company
meeting

Psychologists and
non-prescribing
clinical team

Project
Educational
Presentation

Completion of project;
pre and post tests

Via Zoom

Psychologists and
non-prescribing
clinical team

Project Findings,
Data and
Feedback

Results of project; pre
and posttests.
Incorporation of
materials into resource
aid for group.

Via Zoom

Once, during
weekly
company
meeting
Once, during
weekly
company
meeting

Psychologists and
non-prescribing
clinical team
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Appendix J. SWOT Analysis
Strengths
-Sustainable and low overall cost.
- Use of digital mediums of distribution which the
company already had implemented prior to the
projec
-Unlimited access to presentation
-Established rapport with presentor as is current
student completing clinical hours at company

Weaknesses
-Project outcomes are only as good as the
providers using, reinforcing, and ultimately
dedicating time to learn the information
-Previous provider education and interest on the
topics varies ; varied enthusiasm to learn

SWOT

Opportunities

Threats

-Initiation of resource space for providers
expanded by the contributions of providers
according to their expertise and knowledge

-Psychopharmacology and the learnings provided
in this project require time and continued
education.

- Opportunity for providers to implement their
knowledge and education to other members of
the team.

-Providers may also benefit from continuous
learning and presentations which requires alloted
time
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Appendix K. Proposed Budget
Proposed Budget

Per Item Cost

Amount/Hours
Needed

Material Items Cost Breakdown
9 (8 for
Electronic Device (Every provider
$350
participants, 1 for
supplied their own device)
presenter)
WIFI/ Internet Access (Every provider
supplied their own; budgeted here is
an iPad)

$600/year

9 (8 for
participants, 1 for
presenter)

Thank-you cards sent to participants
and co-founders

$1

Pens

$1

10 (8 for
participants, 2 for
co-founders)
10

Paper/journals for notetaking

$1

10

Projected
Cost

Actual
Adjusted
Cost
(Excludes
items
provided by
company)

$3,150

$0

$5,400

$0

$10

$10

$10

$10

$10

$10

9 (8 for
participants, 1 for
$1,350
presenter)
Time Cost Breakdown (Aside from clinical and student hours)
Assessment of need for project at
$65
35
$2,275
clinical site
Zoom Professional Subscription
(provided by the company)

$150/year

$0

$2,275

Meeting with Co- Founders (Initial)

$65

2

$130

$130

Introductory meeting to introduce
student/project to psychologists

$65

1

$65

$65

Research for Educational
Presentation

$65

15

$975

$975

Creation of Educational Presentation

$65

2

$130

$130

Creation of Pre and Post Tests

$65

2

$130

$130

Project Implementation/Presentation

$65

2

$130

$130

Gathering of Data/Results

$65

5

$325

$325

Creation of resources for continued
access/resource library

$65

2

$130

$130

Meeting time to share results with
team/gather feedback

$65

2

$130

$130

$14,350

$5,800

Project Total
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Appendix L. PDSA Cycle
•Curate educational
prsentation based on gap
analysis of company
•Update resource library
available post
presentation to providers

•Create action plan to
present to advisor and cofounders
•Create educational
presentation
•Create pre and post test
•Include opportunity for
feedback

Act

Study
•Gather and compile data
from the pre and post
tests
•Survey trends in data
compiled and insight
gleaned from project

Plan

Do
•Implement educational
presentation to increase
knowledge of
psychopharmacology
among non-prescribers
•Cross collaborate
members on the team
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Appendix M. Survey Results: Pre-Test Responses
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8. Any additional comments or questions? 8 responses
Please make interactive presentation. Thank you.
interesting topic, never thought of learning more.
Will we have access to the presentation afterward? Where can we learn more?
Will there be other presentations like this?
How can we contact you if we have other questions?
looking forward to this.
such an interesting topic
I want to learn more about this.
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Appendix N. Survey Results and Feedback: Post-Test Responses
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73

8. Any additional comments or questions?8 responses
super helpful! thanks
it's great to have you on the team
THANK YOU
this was great, thank you for the resources
I hope we can do this again soon in group
I appreciate you sharing this information and taking the time. It's important for the work we do
with clients.
Many of my clients are on medication. This was a good starting point and now I feel I have more
curiosity about the topic.
We should continue doing sessions like this; it's engaging when it is interactive.
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Appendix O. Bar Graph Indicating Confidence Levels on Pre and Post Test
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Appendix P. Pre-Test Qualitative Results: Thoughts and Comments Word Cloud
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Appendix Q. Post-Test Qualitative Results: Thoughts and Comments Word Cloud
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Appendix R. Educational Presentation
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